http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7767642-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b16cc3b66c4adc826cb79feb4c936b1b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
filingDate 2006-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5729d1883b14779c818ea490a88c8cb2
publicationDate 2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-7767642-B2
titleOfInvention Therapeutic peptides for the treatment of metastatic cancer
abstract Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11116851-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10066004-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017070092-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9034815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010098760-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012051247-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011014195-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9585938-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129345-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008241125-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012051247-A3
priorityDate 2005-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02058450-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004092339-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005282744-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394204
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226504574
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226086
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129862661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6331297
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136039228
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281670
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409975
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409598
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID320930
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394205
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396057

Total number of triples: 53.